Claims
- 1. A substituted basic 2-aminotetralin of the formula ##STR124## in which R.sup.1 represents hydrogen or alkyl,
- R.sup.2 represents hydrogen, alkyl or acyl, and
- R.sup.3 represents a group of the formula --(CH.sub.2).sub.a --R.sup.4, --CH.sub.2 --CH.dbd.CH--(CH.sub.2).sub.b --R.sup.4, --CH.sub.2 --C.tbd.C--(CH.sub.2).sub.b --R.sup.4 or ##STR125## wherein a denotes a number from 1 to 10, and
- b denotes a number 0, 1, 2, 3, or 4,
- R.sup.4 denotes --NR.sup.11 R.sup.12,
- R.sup.11 and R.sup.12, together with the nitrogen atom, form a ring selected from the group consisting of ##STR126## or its salt.
- 2. A substituted basic 2-aminotetralin or salt according to claim 1, wherein
- R.sup.1 represents hydrogen or lower alkyl,
- R.sup.2 represents hydrogen, lower alkyl, lower alkylcarbonyl, or benzoyl, and
- R.sup.3 represents a group of the formula --(CH.sub.2).sub.a --R.sup.4, --CH.sub.2 --CH.dbd.CH--(CH.sub.2).sub.b --R.sup.4, --CH.sub.2 --C.tbd.C--(CH.sub.2).sub.b --R.sup.4 or ##STR127## wherein a denotes a number 1 to 8, and
- b denotes a number 0, 1, 2 or 3.
- 3. A substituted basic 2-aminotetralin or salt according to claim 1, wherein
- R.sup.1 represents hydrogen or methyl,
- R.sup.2 represents hydrogen, methyl, ethyl, propyl, isopropyl, acetyl or propionyl, and
- R.sup.3 represents a group of the formula --(CH.sub.2).sub.a --R.sup.4, --CH.sub.2 --CH.dbd.CH--(CH.sub.2).sub.b --R.sup.4, --CH.sub.2 --C.tbd.C--(CH.sub.2).sub.b --R.sup.4 or ##STR128## wherein a denotes a number 1 to 6, and
- b denotes a number 0, 1 or 2, and
- R.sup.11 and R.sup.12, together with the nitrogen atom, form a ring selected from the group consisting of ##STR129##
- 4. A compound according to claim 1 wherein NR.sup.11 R.sup.12 represents ##STR130##
- 5. A composition for treatment of a disorder of the central nervous system, the cardiovascular system or the intestinal tract comprising an amount effective therefor of a compound or salt according to claim 1 and a physiologically acceptable diluent.
- 6. A unit dose of a composition according to claim 5, in the form of a tablet, ampule or capsule.
- 7. A method of treating a patient suffering from a disorder of the central nervous system, the cardiovascular system or the intestinal tract comprising administering to such patient an amount effective therefor of a compound or salt according to claim 1.
Priority Claims (2)
Number |
Date |
Country |
Kind |
3642192 |
Dec 1986 |
DEX |
|
2718371 |
Jun 1987 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 07/682,823, filed Apr. 9, 1991, now U.S. Pat. No. 5,153,225 which is a division of application Ser. No. 378,733, filed Jul. 12, 1989, now U.S. Pat. No. 5,026,857, which is a division of application Ser. No. 130,373, filed Dec. 8, 1987, now U.S. Pat. No. 4,880,802.
US Referenced Citations (12)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0041488 |
May 1981 |
EPX |
Non-Patent Literature Citations (8)
Entry |
M. B. Emerit, European Journal of Pharmacology, 127, 1986, pp. 67-891. |
M. B. Emerit, Biochemical Pharmacology, vol. 34, 1985, pp. 883-892. |
Chemical Abstracts, vol. 106, 1987, p. 94. |
Robins and Walker, J. Chem. Soc., "A New and Specific Aromatisation Reaction. Part III Aromatisation 1:4-Dioxocyclohexane Rings," 1958, pp. 409-421. |
John W. Cornforth, J. Chem. Soc., 1942, pp. 689-691. |
Theodora W. Greene, Protective Groups in Organic Synthesis, 1981, p. 89. |
W. Clark Still, J. Org. Chem., 1978, pp. 2923-2925. |
W. Clark Still, Aldrichimica Acta, vol. 18, 1985, p. 25. |
Divisions (3)
|
Number |
Date |
Country |
Parent |
682823 |
Apr 1991 |
|
Parent |
378733 |
Jul 1989 |
|
Parent |
130373 |
Dec 1987 |
|